The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

The second edition of the AI ​​Day served to share knowledge, reflect and chart the future of artificial intelligence applied to research and health.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

The study, led by Vall d'Hebron, is the first in Spain to analyse the relationship between pregnancy complications and the risk of long-term cardiovascular diseases.

The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.

Vall d'Hebron researchers have created a score based on multiple clinical variables and cardiac images, specific to women, to identify patients at risk of severe complications such as a heart attack or sudden death.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The study on the effects of diesel particles on the heart has been recognized as the best research work from Spain at the association’s Scientific Sessions.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

The funds will strengthen research lines focused on nervous system tumors.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.